TargetMol

Revefenacin

Product Code:
 
TAR-T7392
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T7392-1mg1mg£109.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7392-2mg2mg£128.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7392-5mg5mg£155.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7392-1mL1 mL * 10 mM (in DMSO)£164.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7392-10mg10mg£213.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7392-25mg25mg£334.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7392-50mg50mg£462.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7392-100mg100mg£630.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Revefenacin is a mAChR antagonist has a high affinity on M3 receptor( Ki : 0.18 nM),and potentially useful for the treatment of respiratory disease.
CAS:
864750-70-9
Formula:
C35H43N5O4
Molecular Weight:
597.76
Pathway:
Neuroscience
Purity:
0.9666
SMILES:
CN(CCN1CCC(CC1)OC(=O)Nc1ccccc1-c1ccccc1)C(=O)c1ccc(CN2CCC(CC2)C(N)=O)cc1
Target:
AChR

References

Pudi KK, Barnes CN, Moran EJ,et al.A 28-day, randomized, double-blind, placebo-controlled, parallel group study of nebulized revefenacin in patients with chronic obstructive pulmonary disease[J].Respir Res. 2017 Nov 2;18(1):182. Pulido-Rios MT, McNamara A, Obedencio GP,et al.In vivo pharmacological characterization of TD-4208, a novel lung-selective inhaled muscarinic antagonist with sustained bronchoprotective effect in experimental animal models[J].J Pharmacol Exp Ther. 2013 Aug;346(2):241-50.